首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1448374

全球细胞化验分析市场规模、份额和成长分析：按产品/服务、应用和最终用途 - 产业预测（2024-2031）

Global Cell-Based Assays Market Size, Share, Growth Analysis, By Products & Services, By Application, By End-Use - Industry Forecast 2024-2031

出版日期: 2024年03月04日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球细胞化验分析市场规模将为176亿美元，从2023年的191.4亿美元成长到2031年的374.4亿美元，预测期（2024-2031）预计复合年增长率为8.75%。

全球研究格局，包括重大临床试验和药物发现工作，在 COVID-19 大流行期间遭受了严重破坏。为了解决研究积压问题，世界各地的研究人员迅速采用了更有效率、时间敏感度较低的方法。已经开发了许多专门用于检测 COVID-19 感染的细胞化验分析，其中一些已获得 FDA核准在全球紧急使用。一个例子是 Adaptive Biotechnologies 的 T-Detect COVID-19 常规 T 细胞检测，该检测于 2021 年 5 月获得美国FDA 的紧急使用授权。这种基于次世代定序 (NGS) 的创新测试有助于识别识别 SARS-CoV-2 抗原并确认近期感染的 T 细胞。

基于细胞的药物筛检分析对于药物发现研究至关重要，有助于从庞大的化合物库中仔细选择有前途的候选药物。这些检测涵盖了不同的频谱，受到不同药物开发轨迹中多方面考虑的影响。药物发现研究方面取得的有希望的进展，例如弗劳恩霍夫研究所研究人员于 2022 年 9 月宣布的一项突破性进展 Prooxyrugs，将有助于解决感染疾病、癌症和阿兹海默症等病理。我们强调细胞化验分析在利用废弃物处理方面的多功能性系统并推动科学创新和治疗方法进步。

由于药物发现需求不断增长、生物技术研究需求不断增加以及感染疾病、癌症、自体免疫疾病和遗传异常发病率不断增加等因素，该市场目前预计将强劲成长。细胞化验分析在药物发现过程中发挥着至关重要的作用，不仅可以检验潜在的候选药物，还可以分析先导化合物、分析细胞讯号传导和评估毒性。一个例子是 Cell Biologics 的膜联蛋白 V-Cy3 细胞凋亡检测套件，它使用萤光来检测细胞凋亡。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2021年）
主要市场参与者所采取的策略
关键成功策略
近期市集活动
主要企业市场占有率（2021年）

主要企业简介

Thermo Fisher Scientific, Inc.（United States）
Promega Corporation（United States）
Merck KGaA（Germany）
PerkinElmer, Inc.（United States）
Danaher Corporation（United States）
Cell Signaling Technology, Inc.（United States）
Bio-Rad Laboratories, Inc.（United States）
Agilent Technologies, Inc.（United States）
GE Healthcare（United Kingdom）
Lonza Group Ltd.（Switzerland）

简介目录

Product Code: SQMIG35H2154

Global Cell-Based Assays Market size was valued at USD 17.6 billion in 2022 and is poised to grow from USD 19.14 billion in 2023 to USD 37.44 billion by 2031, growing at a CAGR of 8.75% during the forecast period (2024-2031).

The global landscape of research, encompassing major clinical trials and endeavors in drug discovery, underwent significant disruptions amid the COVID-19 pandemic. In response to research backlogs, researchers globally swiftly embraced efficient and time-sensitive methodologies. Numerous cell-based assays tailored for detecting COVID-19 infections were developed, with several gaining FDA approval for global emergency use. An illustrative instance is the T-Detect COVID-19 routine T-cell test by Adaptive Biotechnologies, obtaining Emergency Use Authorization from the U.S. FDA in May 2021. This innovative Next-Generation Sequencing (NGS)-based test facilitates the identification of T-cells recognizing SARS-CoV-2 antigens, confirming recent infections.

Cell-based drug screening assays have been integral in drug discovery research, facilitating the careful selection of promising drug candidates from extensive compound libraries. These assays cover a diverse spectrum, influenced by multifaceted considerations in various drug development trajectories. Anticipated advancements in drug discovery, such as the groundbreaking development unveiled in September 2022 by Fraunhofer Institute researchers-Proxidrugs-highlight the versatility of cell-based assays in driving scientific innovation and therapeutic evolution, harnessing waste disposal systems to address conditions like infections, cancer, and Alzheimer's disease.

The market is currently poised for robust growth due to factors like a rising demand for drug discovery, an increased need for biotechnology research, and the growing incidence of infectious diseases, cancer, autoimmune disorders, and genetic anomalies. Cell-based assays play a pivotal role in the drug discovery process, not only for validating potential drug candidates but also for lead profiling, analyzing cellular signaling, and assessing toxicity. An exemplary illustration is The Annexin V-Cy3 apoptosis detection kit by Cell Biologics, utilizing fluorescence to detect apoptosis-a testament to the diverse applications of these assays in comprehensive cellular analysis.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell-Based Assays Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell-Based Assays Market Segmental Analysis

The global cell-based assays market is segmented on the basis of product & services, application, end - use, region. By product & services, the market is segmented into reagents, assay kits, cell growth assays, reporter gene assays, cell death assays, second messenger assays, microplates, probes & labels, instruments & software, cell lines, primary cell lines, stem cell lines, immortalized cell lines. By application, the market is segmented into basic research, drug discovery, other applications. By end - use, the market is segmented into pharmaceutical and biotechnology companies, academic & research institutes, contract research organizations. By region, the market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.

Drivers of the Global Cell-Based Assays Market

The rising incidence of chronic conditions like cancer, cardiovascular diseases, and neurodegenerative disorders is driving the need for sophisticated cell-based assays in disease modeling and drug testing.

Restraints in the Global Cell-Based Assays Market

Creating and executing cell-based assays can be demanding in terms of resources, as expenses related to reagents, equipment, and proficient personnel can present obstacles, especially for smaller research organizations.

Market Trends of the Global Cell-Based Assays Market

The trend towards utilizing 3D cell culture models that closely mimic physiological conditions is increasingly gaining momentum. This shift facilitates a more accurate replication of in vivo environments, thereby enhancing the efficacy of drug screening and toxicity assessment processes.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Cell-Based Assays Market by Products & Services

Market Overview
Reagents
Assay Kits
Cell Growth Assays
Reporter Gene Assays
Cell Death Assays
Second Messenger Assays
Microplates
Probes & Labels
Instruments & Software
Cell Lines
Primary Cell Lines
Stem Cell Lines
Immortalized Cell Lines

Global Cell-Based Assays Market by Application

Market Overview
Basic Research
Drug Discovery
Other Applications

Global Cell-Based Assays Market by End-Use

Market Overview
Pharmaceutical and Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations

Global Cell-Based Assays Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Thermo Fisher Scientific, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Promega Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cell Signaling Technology, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza Group Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments